Evidence map›Paper›PMID 32207041›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm.

I Meattini, N Andratschke, A M Kirby, G Sviri, B V Offersen, P Poortmans, O Kaidar Person

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 5 countries.

I MeattiniDepartment of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. icro.meattini@unifi.it.ORCID https://orcid.org/0000-0002-1861-2895
N AndratschkeUniversity Hospital of Zurich, The University of Zurich, Zurich, Switzerland.
A M KirbyRoyal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
G SviriNeurosurgery Department, Rambam Medical Center, Haifa, Israel.
B V OffersenDepartment of Experimental Clinical Oncology, Aarhus University, Aarhus C, Denmark.
P PoortmansUniversité Paris, Sciences et Lettres, Paris, France.
O Kaidar PersonSheba Tel Hashomer, Ramat Gan, Israel.
Aarhus University · DKAzienda Ospedaliero-Universitaria Careggi · ITInstitute of Cancer Research · GBRambam Health Care Campus · ILSheba Medical Center · ILUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the leading cause of brain metastases in women. Large randomized clinical trials that have evaluated local therapies in patients with brain metastases include patients with brain metastases from a variety of cancer types. The incidence of brain metastases in the breast cancer population continues to grow, which is, aside from the rising breast cancer incidence, mainly attributable to improvements in systemic therapies leading to more durable control of extracranial metastatic disease and prolonged survival. The management of breast cancer brain metastases remains challenging, even more so with the continued advancement of local and highly effective systemic therapies. For most patients, a metastases-directed initial approach (i.e., radiation, surgery) represents the most appropriate initial therapy. Treatment should be based on multidisciplinary team discussions and a shared decision with the patients taking into account the risks and benefits of each therapeutic modality with the goal of prolonging survival while maintaining quality of life. In this narrative review, a multidisciplinary group of experts will address challenging questions in the context of current scientific literature and propose a therapeutic algorithm for breast cancer patients with brain metastases.

Indexed as

AlgorithmsBrain NeoplasmsBreast NeoplasmsCranial IrradiationFemaleHumansBrain metastasesBreast cancerCraniotomyRecommendationsStereotactic radiation therapySystemic therapy

Identifiers

PMID32207041
OpenAlexW3012875762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.